EUFLEXXA 3x2ml – Hyaluronic acid gel for joints

<h3>Comprehensive Presentation of the Product EUFLEXXA</h3>
<p>EUFLEXXA is a medical device designed for viscosupplementation of joints, particularly the knee, in cases of osteoarthritis. This injectable solution is based on highly purified hyaluronic acid, developed without animal origin, which reduces the immunogenic potential and the risks of allergic reactions associated with animal proteins. Marketed by Ferring Pharmaceuticals, EUFLEXXA is intended exclusively for professional medical use and is not meant for self-administration by patients. The product offers an alternative to purely symptomatic treatments for arthritic pain, such as analgesics or non-steroidal anti-inflammatory drugs. Viscosupplementation with hyaluronic acid is recognized in many therapeutic protocols to improve joint mobility and reduce pain associated with cartilage degradation.</p>
<p>The hyaluronic acid contained in EUFLEXXA is of high purity, obtained through bacterial fermentation, and has physicochemical characteristics similar to physiological synovial fluid. The device is presented in the form of sterile pre-filled syringes of 2 mL, intended to be injected directly into the target joint. The typical packaging contains three syringes allowing for a complete treatment cycle, with each injection spaced approximately one week apart, according to the laboratory's recommendations and current clinical practice.</p>
<p>EUFLEXXA is subject to strict manufacturing standards and meets European regulatory requirements for medical devices (CE marking). This ensures traceability, safety, and efficacy of the product when used under conditions compliant with the recommendations. The solution is transparent, viscoelastic, and sterile, ensuring good intra-articular tolerance without the injection of animal substances. The sterility and stability of the product are guaranteed as long as it is stored within the indicated temperature range (2°C to 25°C).</p>
<ul><li>Non-animal hyaluronic acid, obtained from microbial fermentation</li><li>Concentration: 10 mg/mL (1%) in a physiological buffered solution</li><li>Packaging: box of 3 pre-filled syringes of 2 mL each</li><li>Indicated for the treatment of knee osteoarthritis pain</li><li>Injection strictly reserved for healthcare professionals trained in the technique</li><li>Sterile and apyrogenic product, compliant with CE standards</li><li>Improves the viscosity and elasticity of joint synovial fluid</li><li>Solid scientific and clinical basis for efficacy in pain reduction</li><li>Not indicated for other joints unless advised by a physician</li><li>Requires storage between 2°C and 25°C</li><li>No animal proteins, reduces immunogenic risk</li><li>Administration route is intra-articular only</li><li>For professional use only</li></ul>
<p>In conclusion, EUFLEXXA represents a recognized option in the non-surgical management of knee osteoarthritis, through a biomimetic approach that respects joint structures and aims to restore the rheological properties of synovial fluid. This product must be used in accordance with the manufacturer's technical data sheet and under appropriate medical supervision to ensure safety, efficacy, and regulatory compliance in France.</p>

<h3>Detailed Instructions for EUFLEXXA</h3>
<p>This product is a class III implantable medical device. Intended for the exclusive use of qualified healthcare professionals. EUFLEXXA is intended for viscosupplementation by intra-articular injection, primarily in the treatment of pain related to knee osteoarthritis. The usual protocol recommends one injection per week for three consecutive weeks, at a rate of 2 mL per session under strict asepsis. The injection must be performed by a physician or a healthcare professional duly trained in the joint injection technique, in accordance with the manufacturer's specific instructions and the product data sheets.</p>
<p>Before the procedure, a prior consultation with the patient is essential to confirm the indication for viscosupplementation, to exclude any contraindications or ongoing joint infections, and to explain the objectives as well as the steps of the treatment. On the day of the intervention, the area to be injected must be carefully disinfected. It is possible to evacuate a joint effusion before administering EUFLEXXA. The intra-articular injection is performed according to the conventional technique (lateral, superior, or medial approach depending on the patient's anatomy).</p>
<ul><li>Recommended dosage: 1 syringe (2 mL) in the knee joint, once a week for 3 weeks</li><li>Administration must be done under sterile conditions in a medical office</li><li>Strict adherence to the aseptic protocol during the injection</li><li>Use in patients with active infection in the affected joint is contraindicated</li><li>Post-injection monitoring is necessary to detect any local or general reaction</li><li>In case of effusion, perform a puncture before injection</li><li>The product is not suitable for self-medication or self-injection</li><li>Maintain the product storage between 2°C and 25°C until the time of use</li></ul>
<p>After the procedure, short-term medical monitoring is recommended to ensure the absence of acute reaction. The practitioner must inform the patient of the normal sensations to expect, such as slight discomfort, transient localized pain, and recommendations for the gradual resumption of activities. The application of ice or a compressive bandage may be considered if post-injection pain occurs. Adhering to all these steps maximizes the safety and effectiveness of the procedure.</p>

<h3>Detailed Composition of EUFLEXXA</h3>
<p>EUFLEXXA is formulated exclusively from selected components for their biocompatibility and safety of use in the joint environment. The main active ingredient is hyaluronic acid, a substance naturally present in the synovial fluid of the human joint. This hyaluronic acid is produced by bacterial fermentation, with no animal origin, which limits the risk of allergy or pathogen transmission. Each pre-filled syringe contains 2 mL of 1% hyaluronic acid gel (i.e., 20 mg per syringe), in a buffered saline solution to match the physiological osmolality of the synovial fluid. No preservatives, animal proteins, or unnecessary additives are present in the formulation.</p>
<p>The choice of purified microbial-origin hyaluronic acid aims to ensure excellent biological tolerance and optimal assimilation by the joint, limiting the occurrence of serious adverse events. The macromolecular structure of the hyaluronic acid used gives it specific viscoelastic properties, similar to those of normal synovial fluid observed in young adults. This allows for lubrication of the joint, cushioning of mechanical shocks, and support of joint function during daily movements.</p>
<ul><li>Hyaluronic acid (20 mg/2 mL) – high molecular weight molecule, derived from bacterial fermentation</li><li>Buffered saline solution (sodium chloride, disodium phosphate, monosodium phosphate, water for injection preparations)</li><li>Complete absence of animal-derived proteins</li><li>Absence of preservatives (parabens, phenol, etc.)</li><li>Sterile and pyrogen-free product</li><li>pH adjusted to ensure compatibility with synovial tissues</li><li>Osmolality suitable for native synovial fluid</li></ul>
<p>All excipients and the active ingredient comply with current European standards for medical devices for intra-articular use. The concentration and viscosity of the EUFLEXXA gel are specially calibrated to ensure prolonged retention in the joint and optimize its therapeutic effect. Before administration, each batch undergoes sterility and quality controls to guarantee the absence of biological or chemical contaminants.</p><p>In conclusion, EUFLEXXA provides a safe and proven approach to viscosupplementation, based on a composition perfectly suited to the current requirements of orthopedic and rheumatological medicine.</p>

<h3>Precautions for Use and Contraindications of EUFLEXXA</h3>
<p>EUFLEXXA has a very good tolerance profile; however, certain precautions must be observed to avoid any complications or misuse. This medical device is not indicated for individuals with a known hypersensitivity to hyaluronic acid or to any of the components of the saline solution. In the absence of animal proteins, the risk of specific allergic reactions is significantly reduced, but the possibility of individual intolerance remains, although it is rare.</p>
<p>The presence of a local or systemic infection, particularly at the site of the joint to be treated, constitutes a strict contraindication to the use of the product, as does any situation of dermatosis or skin lesion at the injection site. Pregnancies, breastfeeding, and use in children have not been the subject of sufficient clinical studies to guarantee safety outside of validated indications.</p>
<ul><li>Known allergy to hyaluronic acid: formal contraindication</li><li>History of severe allergic reaction to an injectable medical device</li><li>Ongoing joint infection (arthritis, septic effusion, etc.)</li><li>Presence of a skin lesion, dermatosis, or eczema at the injection site</li><li>Use not recommended during pregnancy and breastfeeding unless advised by a specialist</li><li>Not indicated for children or adolescents outside of a validated framework</li><li>Risk of local reactions: redness, swelling, transient pain, rare hematoma</li><li>Recent monitoring after injection (15-30 minutes in the office)</li></ul>
<p>In case of doubt or a significant allergic history, the prior performance of a tolerance test under medical supervision may be considered. The healthcare professional must obtain a detailed medical history and inform the patient about the actions to take in case of adverse reactions post-injection.</p>

<h3>Detailed Benefits of EUFLEXXA</h3>
<p>EUFLEXXA provides specific support for pain related to knee osteoarthritis by restoring optimal viscosity of the synovial fluid through highly purified hyaluronic acid. This treatment primarily aims to improve joint mobility and reduce painful episodes associated with cartilage degeneration. Several clinical studies have demonstrated the product's effectiveness in providing lasting pain relief and functional improvement of the knee, without resorting to surgical treatment or long-term anti-inflammatory medications.</p>
<p>The main benefits identified are:</p>
<ul><li>Restoration of the natural viscosity of the synovial fluid in the knee joint</li><li>Significant reduction of arthritic pain, with an effect that can last several months after a complete injection cycle</li><li>Improvement in mobility, flexibility, and overall quality of life for arthritic patients</li><li>Decrease in the use of analgesics and anti-inflammatories, including NSAIDs</li><li>Non-surgical product, thus avoiding surgical risks or hospitalization</li><li>Superior biocompatibility due to the absence of animal proteins, limiting immune and allergic reactions</li><li>Sterile solution compliant with regulatory standards for optimal safety during administration</li><li>Biomimetic effect, reproducing the properties of physiological synovial fluid</li><li>Tolerance demonstrated in numerous multicenter clinical trials</li><li>Facilitates outpatient management, without prolonged interruption of daily activities</li><li>Clear and specific indication for knee osteoarthritis, allowing for precise patient/practitioner selection</li></ul>
<p>In summary, EUFLEXXA fits into the modern therapeutic arsenal for knee osteoarthritis, offering a relevant alternative to traditional medication protocols. This positive effect, validated in clinical studies and scientific recommendations, should, however, be part of a comprehensive approach that includes medical evaluation, monitoring, and adherence to indications.</p>